Holy Name Medical Center | Clinical Research Department
Status and phase
Conditions
Treatments
About
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Crossover Inclusion Criteria:
Exclusion criteria
Crossover Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
453 participants in 2 patient groups
Loading...
Central trial contact
Mirati Therapeutics Study Locator Services
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal